Cargando…
P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430742/ http://dx.doi.org/10.1097/01.HS9.0000847368.92731.fb |
| _version_ | 1784779859971538944 |
|---|---|
| author | Nastoupil, L. Morschhauser, F. Scholz, C. W. Bishton, M. Yoon, S.-S. Giri, P. Wei, M. C. Knapp, A. Li, C.-C. Bottos, A. Li, H. Purev, E. Bartlett, N. L. |
| author_facet | Nastoupil, L. Morschhauser, F. Scholz, C. W. Bishton, M. Yoon, S.-S. Giri, P. Wei, M. C. Knapp, A. Li, C.-C. Bottos, A. Li, H. Purev, E. Bartlett, N. L. |
| author_sort | Nastoupil, L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430742 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94307422022-08-31 P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA Nastoupil, L. Morschhauser, F. Scholz, C. W. Bishton, M. Yoon, S.-S. Giri, P. Wei, M. C. Knapp, A. Li, C.-C. Bottos, A. Li, H. Purev, E. Bartlett, N. L. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430742/ http://dx.doi.org/10.1097/01.HS9.0000847368.92731.fb Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Nastoupil, L. Morschhauser, F. Scholz, C. W. Bishton, M. Yoon, S.-S. Giri, P. Wei, M. C. Knapp, A. Li, C.-C. Bottos, A. Li, H. Purev, E. Bartlett, N. L. P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| title | P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| title_full | P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| title_fullStr | P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| title_full_unstemmed | P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| title_short | P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA |
| title_sort | p1125: celestimo: a phase iii trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430742/ http://dx.doi.org/10.1097/01.HS9.0000847368.92731.fb |
| work_keys_str_mv | AT nastoupill p1125celestimoaphaseiiitrialevaluatingtheefficacyandsafetyofmosunetuzumabpluslenalidomideversusrituximabpluslenalidomideinpatientswithrelapsedorrefractoryfollicularlymphoma AT morschhauserf p1125celestimoaphaseiiitrialevaluatingtheefficacyandsafetyofmosunetuzumabpluslenalidomideversusrituximabpluslenalidomideinpatientswithrelapsedorrefractoryfollicularlymphoma AT scholzcw p1125celestimoaphaseiiitrialevaluatingtheefficacyandsafetyofmosunetuzumabpluslenalidomideversusrituximabpluslenalidomideinpatientswithrelapsedorrefractoryfollicularlymphoma AT bishtonm p1125celestimoaphaseiiitrialevaluatingtheefficacyandsafetyofmosunetuzumabpluslenalidomideversusrituximabpluslenalidomideinpatientswithrelapsedorrefractoryfollicularlymphoma AT yoonss p1125celestimoaphaseiiitrialevaluatingtheefficacyandsafetyofmosunetuzumabpluslenalidomideversusrituximabpluslenalidomideinpatientswithrelapsedorrefractoryfollicularlymphoma AT girip p1125celestimoaphaseiiitrialevaluatingtheefficacyandsafetyofmosunetuzumabpluslenalidomideversusrituximabpluslenalidomideinpatientswithrelapsedorrefractoryfollicularlymphoma AT weimc p1125celestimoaphaseiiitrialevaluatingtheefficacyandsafetyofmosunetuzumabpluslenalidomideversusrituximabpluslenalidomideinpatientswithrelapsedorrefractoryfollicularlymphoma AT knappa p1125celestimoaphaseiiitrialevaluatingtheefficacyandsafetyofmosunetuzumabpluslenalidomideversusrituximabpluslenalidomideinpatientswithrelapsedorrefractoryfollicularlymphoma AT licc p1125celestimoaphaseiiitrialevaluatingtheefficacyandsafetyofmosunetuzumabpluslenalidomideversusrituximabpluslenalidomideinpatientswithrelapsedorrefractoryfollicularlymphoma AT bottosa p1125celestimoaphaseiiitrialevaluatingtheefficacyandsafetyofmosunetuzumabpluslenalidomideversusrituximabpluslenalidomideinpatientswithrelapsedorrefractoryfollicularlymphoma AT lih p1125celestimoaphaseiiitrialevaluatingtheefficacyandsafetyofmosunetuzumabpluslenalidomideversusrituximabpluslenalidomideinpatientswithrelapsedorrefractoryfollicularlymphoma AT pureve p1125celestimoaphaseiiitrialevaluatingtheefficacyandsafetyofmosunetuzumabpluslenalidomideversusrituximabpluslenalidomideinpatientswithrelapsedorrefractoryfollicularlymphoma AT bartlettnl p1125celestimoaphaseiiitrialevaluatingtheefficacyandsafetyofmosunetuzumabpluslenalidomideversusrituximabpluslenalidomideinpatientswithrelapsedorrefractoryfollicularlymphoma |